| Document |
Document Title |
|
WO/2023/144782A1 |
A pharmaceutical composition comprising a compound shown in formula (I) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and optionally, a buffer. Additionally provided are a preparation method for the pharmaceutical compos...
|
|
WO/2023/142357A1 |
Disclosed are a drug/siRNA co-delivery nanocomplex, a method for preparing same, and use thereof. The nanocomplex comprises: a nanocore carrying a drug, a cationic polymer coating the nanocore, and siRNA. The nanocomplex may be PD@RPPT/s...
|
|
WO/2023/143399A1 |
Disclosed in the present invention are a steroid compound, and a preparation method therefor and an application thereof. The steroid compound may have a structure as shown in formula XXI, etc. The compound of the present invention has SR...
|
|
WO/2023/144737A1 |
The present invention relates to a pharmaceutical composition for preventing or treating heart failure, comprising a compound represented by formula I, optical isomers thereof or pharmaceutically acceptable salts thereof as an active ing...
|
|
WO/2023/143389A1 |
The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
|
|
WO/2023/146897A1 |
Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular dis...
|
|
WO/2023/143306A1 |
Disclosed are preparation for an ethinylestradiol-cyclodextrin complex and use thereof. The ethinylestradiol-cyclodextrin complex utilizes the properties of cyclodextrin that the inner cavity is hydrophobic and the outer surface is hydro...
|
|
WO/2023/143400A1 |
Provided are a steroid compound, a preparation method therefor and a use thereof. The steroid compound may have a structure as shown in formula VI. The compound has SREBP pathway inhibitory activity, and can be used for preventing and/or...
|
|
WO/2023/143350A1 |
Provided are a crystal form and salt of a phenothiazine compound, a preparation method therefor and a use thereof. A hydrochloride of the phenothiazine compound and a crystal thereof can be used as ferroptosis inhibitors, and the hydroch...
|
|
WO/2023/145860A1 |
Provided is a novel peptide capable of binding to an SCF receptor (c-Kit). This novel peptide is, for example, a peptide having a cyclic or loop structure, wherein the amino acid sequence of the cyclic or loop structure contains an amino...
|
|
WO/2023/143398A1 |
Disclosed in the present invention are a steroid and a preparation method therefor and an application thereof. The steroid may have a structure as shown in formula II. The compound of the present invention has SREBP pathway inhibitory ac...
|
|
WO/2023/143522A1 |
The present invention relates to a nerve repair protein composition. The preparation thereof comprises the following steps: adding 20 U/mL-35 U/mL of any one or a combination of nuclease or totipotent nuclease to a cell protein extract, ...
|
|
WO/2023/145873A1 |
The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (The definitions of R1, R2, L, m and n in formula (I) are stated in the specification.)
|
|
WO/2023/144379A1 |
The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In par...
|
|
WO/2023/142801A1 |
The present invention provides a use of a secreted glycoprotein in inhibiting the activity of a bone morphogenic protein. It has been found in the present invention that when omentin-1 is used in inhibiting a bone morphogenic protein, no...
|
|
WO/2023/143633A2 |
The present invention provides a salvianolic acid A sodium salt hydrate and a preparation method therefor. Specifically, the salvianolic acid A sodium salt hydrate provided by the present invention is a crystal formed by salvianolic acid...
|
|
WO/2023/147449A1 |
Compositions and methods are provided for treating, preventing, and/or alleviating at least one symptom of heart failure with preserved ejection fraction.
|
|
WO/2023/146437A1 |
The invention relates to the field of pharmacy and medicine, specifically to pharmaceutical compositions of anti-TRBV9 antibody. The invention further relates to the use of said compositions for treating a disease or disorder mediated by...
|
|
WO/2023/146771A1 |
Gingerenone A prodrug compounds have a structure according to Formula I, or a pharmaceutically acceptable salt thereof wherein one of R1 and R2 is H or -C(O)-R and the other of R1 and R2 is -C(O)-R. Each R independently is RA or, where R...
|
|
WO/2023/144722A1 |
The present disclosure is directed to methods of reducing the risk of developing Type 2 diabetes and/or treating prediabetes in a patient in need thereof, the method comprising administering to the patient, an effective amount of a sodiu...
|
|
WO/2023/144053A1 |
Compounds of the formula (I) Q1-Q2-Q3 in which Q1, Q2 and Q3 have the meanings indicated in Claim 1, degrade target proteins, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascul...
|
|
WO/2023/143246A1 |
The present invention relates to a polyethylene glycol-modified form of a kinin or a derivative thereof and pharmaceutical use thereof. In one aspect, by means of a PEG modification technology, the half-life of the kinin is greatly prolo...
|
|
WO/2023/143603A1 |
Use of a compound of Formula I for treating atherosclerosis and related diseases, disorders and conditions in a subject in need of such treatment, wherein the subject in need of such treatment is a subject carrying one or more genetic mu...
|
|
WO/2023/138663A1 |
Provided are a chemically modified dsRNA for inhibiting the expression of angiotensinogen (AGT) and a preparation method therefor. Further provided are a pharmaceutical composition, a vector, a cell and a kit containing the dsRNA, and th...
|
|
WO/2023/138066A1 |
Provided in the present invention is the use of an anti-EGFR antibody in the preparation of a drug for preventing and/or treating diseases related to ocular angiogenesis.
|
|
WO/2023/139506A1 |
This invention provides method of treating hypertension in a hypertensive subject, the method comprising administering to the subject a CYP 11β2 beta hydroxylase inhibitor once or twiceper day in an amount sufficient to inhibit 50% or m...
|
|
WO/2023/137885A1 |
Disclosed in the present invention are a compound having pyridoimidazole as the parent nucleus, and a preparation method for and a use of the compound. The compound having pyridoimidazole as the parent nucleus provided by the present inv...
|
|
WO/2023/138541A1 |
Disclosed are a picolinamide PARP inhibitor, and a preparation method therefor and the medical use thereof. Specifically, the present invention relates to a new compound as represented by general formula (1) and/or a pharmaceutically acc...
|
|
WO/2023/141638A1 |
Described are methods for vascular regeneration m a subject with peripheral vascular disease. Described are also methods of treating a wound. The methods can include administering an effective amount of an O-glycnacylation modifier agent...
|
|
WO/2023/138657A1 |
A quinoline amine compound, a preparation method therefor, and the use thereof in medicine. Specifically, the present disclosure relates to a quinoline amine compound represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2023/138695A1 |
The present invention relates to a cathepsin K inhibitor having a structure as shown in formula (0) and/or formula (II), wherein cyanopyrimidine or a ketone serving as an electrophilic group is a key group to exert a good inhibition effe...
|
|
WO/2023/138302A1 |
Provided are a hydantoin compound as represented by formula (I) or a pharmaceutically acceptable salt thereof and the medical use thereof. The compound has a strong agonistic action on PPARα and PPARδ, has a good selectivity to PPARγ,...
|
|
WO/2023/140665A1 |
The present invention provides a pharmaceutical composition for preventing or treating cardiovascular disease, the pharmaceutical composition comprising orlistat as an active ingredient and reducing plant sterol or oxysterol, thereby bei...
|
|
WO/2023/136342A1 |
The present invention provides a cyclic peptide represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, A is selected from ring-forming groups A1-A5; Xaa1 is a residue of an aromatic amino acid; Xaa2 is...
|
|
WO/2023/137395A1 |
The present disclosure refers to a fusion protein having an antibody against Tie-2 or antigen-binding fragment thereof and a vascular endothelial growth factor (VEGF)-binding domain, methods for making the fusion protein, and pharmaceuti...
|
|
WO/2023/135207A1 |
The present invention relates to a pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a S1P receptor modulator or a pharmaceutically accepta...
|
|
WO/2023/133913A1 |
Disclosed are a method for preparing a multifunctional pea peptide and the use thereof, which belong to the technical field of biomedicine. The method for preparing a multifunctional pea peptide comprises the following steps: S1, prepara...
|
|
WO/2022/136851A9 |
The present invention relates to the use of a reduced folate, such as 5-MTHF (5- methyltetrahydrofolate), optionally in combination with tetrahydrobiopterin (BH4) or precursors thereof, for preventing or treating disorders associated wit...
|
|
WO/2023/135603A1 |
Compounds capable of interacting with the calmodulin-PIP2 binding domain of the SK4 channel to thereby interfere with the Ca2+-dependent activation of the SK4 channel and uses thereof in downregulating an activity of an SK4 channel in a ...
|
|
WO/2023/134713A1 |
The present invention belongs to the field of medicines, and relates to a fused azaheterocyclic compound, a pharmaceutical composition thereof and the use thereof in the preparation of a drug. Specifically, the present invention relates ...
|
|
WO/2023/134682A1 |
The present invention provides an optically active 2-hydroxytetrahydrothienopyridine derivative, and introduces various derivatives of a new 2-hydroxytetrahydrothienopyridine by means of the modification of the structure of clopidogrel, ...
|
|
WO/2023/134090A1 |
The present invention discloses a method for enhancing angiogenesis and osteogenesis using a neuropeptide so as to treat bone-injury disease. The present invention also provides a recombinant protein comprising a neuropeptide and a prote...
|
|
WO/2023/135583A1 |
The present invention relates to vitamin nanoclusters (NCs), preferably vitamin D3nanoclusters, having a core-shell structure in which the solid core comprises vitamin, thereby defining a high-density or high-concentrated vitamin core. T...
|
|
WO/2023/134732A1 |
It provides 2- (diethylamino) ethyl acetoxybenzoate hydrochloride, other high penetration prodrugs of aspirin and other NSAIDs, and pharmaceutically acceptable salts thereof for use and methods thereof in the prevention or treatment of c...
|
|
WO/2023/134673A1 |
A high-selectivity KCNQ4 potassium channel agonist of formula I, a preparation method therefor and the use thereof. The compound further improves the KCNQ4 agonistic activity, and is still free of KCNQ2 agonistic activity, thus having ex...
|
|
WO/2023/133607A1 |
A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium; ii. a diluent in a concentration from 30 to 70 % w/w; i...
|
|
WO/2023/134325A1 |
A lipid compound, a composition containing same, and a use, the lipid compound being prepared by means of a ring-opening reaction of organic amine and glycidyl ester, and the structure not containing free amino groups. The lipid compound...
|
|
WO/2023/134688A1 |
A salt of a ROCK inhibitor, a crystal form of the salt, a composition, and a pharmaceutical use. The salt and the crystal form of the salt are an acid addition salt of a compound I and any acid in the following and a crystal form thereof...
|
|
WO/2023/134656A1 |
Provided are a peptidyl nitrile compound and a use thereof; specifically provided are a compound represented by formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
|
|
WO/2023/135533A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: Formula (I) wherein R is chosen from • - phenyl, a 6-membered heteroaryl group, cyclohexyl, a 5- membered heteroaryl group; • ...
|
